Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

AnHeart to Use Guardant’s Assays for NSCLC Trials of ROS1 Inhibitor

publication date: Feb 2, 2023

Hangzhou AnHeart Therapeutics, a precision medicine company, formed a collaboration to use two assays developed by Palo Alto’s Guardant Health as companion diagnostics to its ROS1 inhibitor. AnHeart is conducting a global Phase II trial of taletrectinib in the US and EU. The trial is aimed at non-small cell lung cancer patients who are ROS1 positive – about 2% of the NSCLC population. Patients will be screened by Guardant360® CDx, an approved circulating blood DNA test, and the tissue-based Guardant360 TissueNext™ assay. In mid-2021, AnHeart out-licensed China rights for the ROS1 candidate to Innovent for $189 million in upfront and milestone payments. More details....

Stock Symbol: (NSDQ: GH)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital